We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medicines Company | NASDAQ:MDCO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.90 | 84.00 | 84.94 | 0 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Medicines Co. (MDCO) shares rose 26% to $73.98 premarket.
Bloomberg reported earlier that Medicines Co. has attracted takeover interest from suitors, including from Novartis AG (NVS), citing people familiar with the matter.
Novartis has been holding talks about a potential acquisition of the company, according to the people, Bloomberg reported. Novartis is conducting due diligence on the company, one of the people said, according to the Bloomberg report.
Officials from Medicines Co. and Novartis declined to comment.
Medicines Co. shares rose 13% Monday. The company said Monday that the ORION-9 study of inclisiran in heterozygous familial hypercholesterolemia patients showed durable low-density lipoprotein cholesterol lowering with twice-yearly dosing.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 19, 2019 08:42 ET (13:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Medicines Chart |
1 Month Medicines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
